HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lieberman, A. N. Articles by Pact, V. Search for Related Content PubMed PubMed Citation Articles by Lieberman, A. N. Articles by Pact, V.

Lisuride combined with levodopa in advanced Parkinson disease

Departments of Neurology (Drs. Lieberman, Neophytides, Gopinathan, Walker, and Pact), Neurochemistry (Dr. Goldstein), and Clinical Medicine (Dr. Leibowitz), New York University School of Medicine, New York, NY.

Address correspondence and reprint requests to Dr. Lieberman, 530 First Avenue, Suite 5A, New York, NY 10016.

lisuride, a semisynthetic ergoline and potent central dopamine and serotinin agonist, was combined with levodopa in 20 patients with advanced Parkinson disease who were no longer responding satisfactorily to levodopa, including 14 patients with "on-off" phenomena. Every patient who completed the week trial improved significantly (p <0.01), with a decrease in all symptoms. The mean dose of lisuride was 2.4 mg per day. The dose of levodopa (mg of levodopa in Sinemet) was reduced from 1030 to 920 mg. Among the patients with "on-off" phenomena, there was a significant increase in the time in which they were "on" (mobile) from 4.6 to 9.6 hours. In 5 of 10 patients who have been on lisuride for at least 1 year, there has been no decline in efficacy.